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Background & Aims: The pathogenesis of nonalcoholic fatty liver disease (NAFLD) is 
affected by epigenetic factors as well as by genetic variation. 
Methods: We performed targeted-bisulfite sequencing to determine the levels of DNA 
methylation of 4 CpG islands (CpG99, CpG71, CpG26, and CpG101) in the regulatory 
regions of PNPLA3, SAMM50, PARVB variant 1, and PARVB variant 2, respectively. We 
compared the levels of methylation of DNA in the livers of the first and second sets of 
patients with mild (fibrosis stages 0 and 1) or advanced (fibrosis stages 2-4) NAFLD and 
in those of patients with mild (F0 to F2) or advanced (F3 and F4) chronic hepatitis C 
infection. The hepatic mRNA levels of PNPLA3, SAMM50, and PARVB were measured 
using qPCR. 
Results: CpG26, which resides in the regulatory region of PARVB variant 1, was markedly 
hypomethylated in the livers of patients with advanced NAFLD. Conversely, CpG99 in the 
regulatory region of PNPLA3 was substantially hypermethylated in these patients. These 
differences in DNA methylation were replicated in a second set of patients with NAFLD or 
chronic hepatitis C. PNPLA3 mRNA levels in the liver of the same section of a biopsy 
specimen used for genomic DNA preparation were lower in patients with advanced 





methylation in liver DNA. Moreover, the levels of CpG99 methylation and PNPLA3 
mRNA were affected by the rs738409 genotype. 
Conclusions: Hypomethylation of CpG26 and hypermethylation of CpG99 may contribute 







Nonalcoholic fatty liver disease (NAFLD) has become a common disease associated with 
metabolic syndrome in the population of developed countries [1, 2] and is accompanied by 
a gradual increase in the frequency of patients presenting with NAFLD [3, 4]. Certain 
people with fatty hepatocytes develop nonalcoholic steatohepatitis (NASH), in which 
hepatic inflammation coincides with increased hepatocyte death [3, 4]. Progressive liver 
fibrosis occurs in certain patients with NASH and markedly increases their risk of liver 
cirrhosis, primary liver cancer, and the resultant liver disease-related morbidity and 
mortality. 
 Genetic and environmental factors affect the development of NAFLD [5]. For 
example, genome-wide association studies (GWASs) reveal that single-nucleotide 
polymorphisms (SNPs) in several loci influence the course of NAFLD and the levels of 
liver enzymes in plasma [6-10]. Comprehensive studies on the SNP rs738409 in the 
patatin-like phospholipase domain containing 3 gene (PNPLA3) verify that this SNP plays 
a key role in the development of NAFLD [11-13]. We performed targeted next-generation 
sequence analysis and fine mapping of the linkage disequilibrium (LD) block containing 
PNPLA3 rs738409 and found that polymorphisms in the genes encoding the SAMM50 





associated with the development and progression of NAFLD as well [14]. Specifically, 
variations in PARVB are associated with hepatocyte ballooning and patients’ fibrosis stage 
[10, 14]. 
 NAFLD is strongly associated with obesity, type 2 diabetes, and dyslipidemia, 
indicating that its pathogenesis is influenced by environmental factors such as excess 
caloric intake. Environmental factors affect DNA methylation, which is an epigenetic form 
of gene regulation typically associated with transcriptional repression [15]. In patients with 
NAFLD, insulin resistance [16] and treatment of obesity [17] affect the DNA methylation 
levels of several genes, and the severity of NAFLD is associated with DNA methylation 
levels [18]. The LD block containing PNPLA3, SAMM50, and PARVB is a crucial genetic 
locus in NAFLD, but epigenetic analysis of human liver DNA in this region has not been 
performed. Because recent improvements to next-generation sequencing enhances its 
ability to evaluate precisely of DNA methylation levels [19], we performed 
targeted-bisulfite sequencing coupled with polymerase chain reaction (PCR) amplification 
to investigate the methylation levels of 4 CpG islands in the genomic region containing the 
regulatory regions of PNPLA3, SAMM50, and PARVB in the livers of patients with NAFLD. 
We analyzed the association of the histological severity of NAFLD with the methylation 





SAMM50, and PARVB. 
 
Patients and methods 
Patients and clinical variables 
This study was conducted in accordance with the guidelines of the Declaration of Helsinki. 
Written informed consent was obtained from each study participant, and the ethics 
committees of Kyoto University and Yokohama City University approved the protocol. We 
enrolled randomly 32 (first set) and 33 (second set) Japanese patients with NAFLD who 
had undergone liver biopsy. The exclusion criteria of NAFLD used in this study were those 
reported previously [10, 14], and NAFLD was diagnosed according to standard criteria 
[20-22]. The degree of steatosis was graded according to the percentage of hepatocytes 
containing macrovesicular fat droplets [23]. The activity of NAFLD was determined 
according to the composite NAFLD activity score (NAS) [24]. Fibrosis severity (0–4) was 
scored according to the method of Brunt [23]. Patients with NAFLD were divided 
according to the fibrosis stage into groups with mild NAFLD (fibrosis stage 0 or 1) or 
advanced NAFLD (fibrosis stages 2 to 4). Patients with chronic hepatitis C (n = 30) were 
included in this study. They underwent liver biopsy, and liver fibrosis was staged according 





groups with mild (F0 to F2) and advanced (F3 or F4) disease. Metabolic syndrome traits 
were diagnosed as reported previously as follows: dyslipidemia, triglyceride level ≥150 
mg/dL and/or high-density lipoprotein (HDL) cholesterol level <40 mg/dL, or under 
treatment for dyslipidemia; hypertension, systolic blood pressure (SBP) ≥130 mmHg 
and/or diastolic blood pressure (DBP) ≥85 mmHg, or under treatment for hypertension; 
and impaired fasting glucose, fasting glucose levels ≥110 mg/dL, or under treatment for 
diabetes [26]. Obesity was diagnosed according to the Japanese obesity criterion of body 
mass index (BMI) ≥25 kg/m2 [27]. Clinical characteristics of patients are presented in 
Table 1. 
Targeted-bisulfite sequencing 
We isolated human genomic DNA and total RNA from the same section of frozen liver 
biopsy specimens and genomic DNA was isolated from whole blood as well. The bisulfite 
reaction was applied to 300 ng of genomic DNA by using the Zymo EZ DNA Methylation 
Kit (Zymo Research, Orange, CA) according to the manufacturer’s protocol. The genomic 
region covering 4 CpG islands CpG99, CpG71, CpG26, and CpG101 (Fig. 1), which reside 
in the regulatory regions of PNPLA3, SAMM50, and PARVB, were amplified from each 
bisulfite-treated DNA sample using region-specific primers (Supplementary Table 1). 





genomic sequence after bisulfite conversion. For the second set of patients with NAFLD or 
chronic hepatitis C, genomic regions including CpG26 and the latter part of CpG99 were 
amplified from each bisulfite-treated DNA sample using unrelated region-specific primers 
(Fig. 1 and Supplementary Table 1). Sequences were amplified using 30 ng of 
bisulfite-converted DNA, 1 × EpiTaq PCR Buffer (Takara Bio Inc., Ohtsu, Japan), 2.5 mM 
MgCl2, 0.3 mM of each dNTP, 0.3 μM of each primer, and 0.375 U of TaKaRa EpiTaq HS 
(Takara) in a 15-μL reaction volume. The PCR was performed for 40 cycles of 98°C for 10 
s, 55°C for 30 s, and 72°C for 2 min. The expected size of PCR amplicons were confirmed 
using agarose gel electrophoresis (Supplementary Fig. 1), and the molar concentrations of 
amplicons were measured using a High Sensitivity NGS Fragment Analysis Kit and 
Fragment Analyzer (Advanced Analytical Technologies, Ames, IA). The amplicons were 
then pooled at an equal concentration for all patients. Pooled PCR products were sheared 
using a Covaris S220 (COVARIS, INC, Woburn, MA) as follows: 10% duty factor, 175 W 
peak incident power, 200 cycles per burst, 180-s duration, and frequency sweeping mode. 
Each sample was dual-indexed, and DNA libraries were prepared using the TruSeq DNA 
Sample Preparation kit v2 (Illumina, San Diego, CA). Samples were sequenced using a 
MiSeq system (Illumina) that performed 100-bp paired-end reads. Sequenced reads of each 





(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The quality of the sequenced 
reads in all libraries was high, with a median Phred score of >31 up to the end of last 
sequencing cycle. Reads of bisulfite-treated DNAs were aligned to the reference human 
genome (UCSC hg19) using Bismark (v0.8.3, 
http://www.bioinformatics.babraham.ac.uk/projects/bismark/) [28], which uses the 
short-read aligner Bowtie 2 (Version 2.1.0, 
http://bowtie-bio.sourceforge.net/bowtie2/index.shtml) [29]. Sequences were used for 
subsequent analysis only if both ends mapped uniquely in the correct orientation. For 
sequence data conversion, sorting, and indexing we used SAMtools (Version 0.1.17; 
http://www.samtools.sourceforge.net/) [30]. To exclude duplicate reads, we used Picard 
(Version 1.72; http://picard.sourceforge.net). Methylated cytosines were extracted from 
deduplicated reads using the Bismark methylation extractor [28]. The aligned reads and 
levels of methylation were visualized using an Integrative Genomics Viewer (IGV Version 
1.5.65, http://www.broadinstitute.org/igv/) [31]. 
RNA isolation and quantitative PCR (qPCR) 
Total RNA was extracted from liver tissue samples using an RNeasy Mini Kit (Qiagen 
GmbH, Hilden, Germany). The quality of RNA was evaluated using an Agilent 2100 





Clara, CA). The RNA Integrity Number of each total RNA sample was >8 [32]. Liver RNA 
samples were reverse-transcribed using a ReverTra Ace qPCR RT Kit (TOYOBO, Osaka, 
Japan). The primer sets used for qPCR are shown in Supplementary Table 2, and qPCR 
was performed using an Applied Biosystems 7500 Fast Real-Time PCR System (Life 
Technologies, Carlsbad, CA) with the THUNDERBIRD SYBR qPCR Mix (TOYOBO). 
Gene expression levels were calculated using the Ct value. We used 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal control and quantified 
the relative mRNA levels using the 2-ΔΔCt method. All experiments were conducted in 
triplicate. 
SNP genotyping 
Invader probes (Third Wave Technologies, Madison, WI) were constructed for rs738409 
and genotyped using the genomic DNA prepared from blood. 
Statistical analysis. 
The clinical data and methylation levels of patients groups with mild or advanced NAFLD 
were compared using t tests, and the methylation levels in liver and blood DNAs were 
compared using paired t tests. The male:female ratio, type 2 diabetes ratios, and the 
presence of metabolic syndrome traits were analyzed using Fisher’s exact test. Statistical 





compare 2 sets of data was performed using fixed-effects model analysis of the 
standardized mean differences using the R package metafor 
(http://www.metafor-project.org http://www.wvbauer.com) [33]. We used the Q-value to 
address the problem of multiple testing, and the Q-value was calculated using Q-VALUE 




Bisulfite sequencing of CpG99, CpG71, CpG26, and CpG101 
We reported that variations in the LD block containing PNPLA3, SAMM50, and PARVB 
critically affect the pathogenesis of NAFLD [10, 14]. Therefore, we determined the 
methylation of 4 CpG islands (CpG99, CpG71, CpG26, and CpG101) in this region (Fig. 
1). First, we amplified and sequenced the genomic region containing these CpG islands 
from 32 liver and 29 whole-blood bisulfite-treated DNA samples (Supplementary Fig. 1). 
The mean coverage of the 4 CpG islands was 1567−3078× in liver and 607−1429× in 
blood samples (Supplementary Fig. 2). We excluded 20 CpG sites in CpG101, because the 
coverage was <50 in ≥2 samples. Methylation of non-CpG sites (CHH and CHG) was 





as optimal for methylation in a non-CpG context (Supplementary Fig. 3 and 
Supplementary Table 3) [35]. We used 117 (CpG99), 66 (CpG71), 42 (CpG26), and 124 
(CpG101) CpG sites for the analysis (Supplementary Table 3) described below. 
Methylation of the DNAs of livers of patients with mild or advanced NAFLD 
We compared the methylation levels between patients with mild or advanced NAFLD in 
the first set (Table 1). Fig. 2 presents the results of liver DNA methylation at each CpG 
base position (bp) in CpG99, CpG71, CpG26, and CpG101. The DNA sequences of the 4 
CpG sites in CpG99 (at bps 44,320,188; 44,320,198; 44,320,329; and 44,320,351) were 
hypermethylated in patients with advanced NAFLD (P < 0.05) (Table 2). Differential 
methylation was most notable in CpG26 and numerous CpG sites were hypomethylated in 
patients with advanced NAFLD (P < 0.05) (Table 3). However, the levels of DNA 
methylation of CpG71 and CpG101 between the 2 groups were not significantly different. 
 To confirm the associations between fibrosis stages and liver DNA methylation 
levels, we investigated methylation levels using the second set of patients with NAFLD (n 
= 33) and performed meta-analysis using the first and second sets. Four CpG sites in 
CpG99 (at bps 44,320,188; 44,320,198; 44,320,329; and 44,320,351) were significantly 
hypermethylated in patients with advanced NAFLD (Q-values < 0.05, Table 2). 





patients with advanced NAFLD (Q-values < 0.05, Table 3). When the first and second sets 
were merged to analyze the DNA methylation levels, the results were very similar to those 
acquired from the meta-analysis. 
 Because SNP rs738409 (I148M) strongly affects the pathogenesis of NAFLD 
[11-13], we examined the methylation levels of the rs738409 (I148M) genotype among 
patients with NAFLD. The first and second sets of patients with NAFLD were divided into 
2 groups according to genotypes (MM vs. IM + II), and the DNA methylation levels were 
compared between patients with mild or advanced NAFLD in each. Methylation levels 
were higher at the 4 CpG sites in CpG99 (at bps 44,320,188; 44,320,198; 44,320,329; and 
44,320,351) in patients with advanced NAFLD compared with those with mild disease in 
the MM genotype group (Supplementary Table 4). No differences in DNA methylation 
levels were observed between patients with mild or advanced NAFLD in the IM + II 
genotype groups (P > 0.05). Methylation levels were lower at the CpG sites in CpG26 in 
patients with advanced NAFLD compared with those with mild disease in the MM and 
IM+II genotype groups (P < 0.05; Supplementary Table 5). 
Methylation of CpG99 and CpG26 in patients with chronic hepatitis C infection 
Liver fibrosis is caused by various hepatic diseases. To determine whether the differential 





methylation levels of liver DNA of patients with chronic hepatitis C. Nine CpG sites in 
CpG99 including the 4 sites (at bps 44,320,188; 44,320,198; 44,320,329; and 44,320,351), 
which were hypermethylated in patients with advanced NAFLD described above, were 
significantly hypermethylated in patients with chronic hepatitis C with fibrosis stage F3 or 
F4 (Q-values < 0.05, Table 2). In CpG26, 26 CpG sites were significantly hypomethylated 
in patients with advanced chronic hepatitis C (Q-values < 0.05, Table 3). These data 
suggest that the differential methylation levels of CpG99 and CpG26 are related to fibrosis 
levels in a liver disease other than NAFLD. 
Methylation of liver and blood DNA and its association with histological phenotypes of 
patients with NAFLD  
We examined the association between histological traits other than fibrosis and the levels 
of liver DNA methylation in patients with mild and advanced NAFLD. None of the CpG 
sites showed significantly different methylation levels in patients with hepatocyte 
ballooning, lobular inflammation, or NAS. 
 To determine whether differential methylation occurred in tissues other than the 
livers of patients with mild or advanced NAFLD, we examined the methylation of DNA 
isolated from blood and found that there were no significant differences in methylation 





with advanced NAFLD (Fig. 3). The methylation levels of liver CpG99 were significantly 
lower compared with those of blood CpG99 of patients in mild or advanced NAFLD 
(Supplementary Fig. 4, Q-values <0.05). The methylation levels of CpG sites in CpG26 in 
liver DNA were significantly higher compared with those of DNA isolated from the blood 
of patients with mild or advanced NAFLD (Q-values <0.05). 
Levels of PNPLA3, SAMM50, and PARVB mRNAs in livers of patients with NAFLD 
Using qPCR, we next measured the mRNA levels of PNPLA3, SAMM50, and PARVB 
variant 1, and PARVB variant 2, respectively (Fig. 1). Total RNAs were prepared from the 
same section of a biopsy that was used to prepare genomic DNA. However, it was not 
possible to prepare sufficient total RNA from the one sample of the second set. The mRNA 
levels of PNPLA3 were significantly lower in patients with advanced NAFLD compared 
with those with mild NAFLD of the first set (P = 0.045; Fig. 4). PNPLA3 mRNA levels 
were lower in patients with advanced NAFLD of the second set (P = 0.051). Meta-analysis 
using the first and second sets of patients with NAFLD showed that the levels of PNPLA3 
mRNA were significantly lower in patients with advanced NAFLD (P = 0.0076). When 
patients with NAFLD were divided into MM and IM+II genotype groups, the levels of 
PNPLA3 mRNA were significantly lower in patients with advanced NAFLD compared 





5). PNPLA3 mRNA levels were lower in patients with advanced NAFLD compared with 
those with mild disease in the group of IM + II genotype group, but the difference was not 
statistically significant. The levels of SAMM50 mRNA did not differ between patients with 
mild or advanced NAFLD. Because CpG26 and CpG101 are located in the upstream 
regions of PARVB variants 1 and 2, respectively, we measured the levels of PARVB variant 
1 and 2 mRNAs separately. We found that PARVB transcript variant 1 was expressed in the 
liver but was undetectable using qPCR because of its low level. The levels of PARVB 
variant 2 mRNA were not significantly different between patients with mild or advanced 
NAFLD. 
 We next investigated the relationship between DNA methylation and mRNA 
levels in patients with NAFLD. PNPLA3 mRNA levels correlated most strongly with the 
methylation levels of CpG99 at bp 44,320,188 (r = -0.442, P = 2.5 × 10-4) (Fig. 4). There 
was a significant correlation between PNPLA3 mRNA and DNA methylation levels in 
patients with NAFLD with the rs738409 MM genotype (r = -0.606, P = 0.0010) 
(Supplementary Fig. 5). There was no significant correlation in patients with NAFLD with 
the II + IM (r = -0.245, P = 0.14) genotypes. These data indicate that the rs738409 







We determined that in patients with advanced NAFLD, CpG26, which lies upstream of the 
coding sequences of the PARVB transcript variant 1, was markedly hypomethylated, 
whereas CpG99 in the regulatory region of PNPLA3 was hypermethylated. The database 
published by Murphy et al. [18] indicates that CpG26 is hypomethylated in patients with 
advanced NAFLD (P = 2.8 × 10-4, bp 44,392,384) and that the methylation levels are 67% 
and 73% in patients with advanced and mild NAFLD, respectively. These findings are 
consistent with our data reported here, and the database [18] indicates further that 
methylation of CpG99 does not differ between patients with mild or advanced NAFLD 
[18]. Because we used the bisulfite sequencing method, we were able to examine almost all 
CpG sites and identify those that were differentially methylated. These differentially 
methylated CpG sites were not included in the Illumina HumanMethylation450 Beadchip 
reported by Murphy et al. [18]. Thus, our approaches may be useful for precisely analyzing 
the DNA methylation levels of CpG islands. Our data and previous data [18] suggest that 
differential methylation of CpG99 and CpG26 is likely to affect the progression of 
NAFLD. 
 NAFLD often accompanies metabolic disorders such as type 2 diabetes, 





syndrome [3]. Metabolic syndrome is mainly caused by an excess intake of calories with a 
contribution from genetic factors. Diet affects DNA methylation and causes diseases such 
as obesity and type 2 diabetes [36], which is consistent with findings that bariatric surgery 
alters DNA methylation levels in the liver [17]. In the present study, a higher percentage of 
patients in the advanced NAFLD group exhibited impaired fasting glucose as well as 
dyslipidemia compared with patients with mild NAFLD. These results suggest that 
dyslipidemia and high blood glucose levels caused by excess caloric intake affect DNA 
methylation levels in the liver. 
 Differential methylation of CpG99 and CpG26 in patients with NAFLD was 
detected in patients studied here with chronic hepatitis C infection. Fibrosis progresses 
during chronic hepatocyte inflammation. Because differential methylation related to 
fibrosis stages was not specific for NAFLD, the DNA methylation levels may be caused by 
hepatic lipid accumulation or chronic hepatitis in contrast to serving as a cause of fibrosis. 
The question of whether differential methylation is a cause or an effect was not answered 
here, and further investigations are required. 
 CpG99 was hypermethylated, and PNPLA3 mRNA levels were lower in patients 
with advanced NAFLD compared with those with mild NAFLD. Therefore, low PNPLA3 





NAFLD. Moreover, we show here that the rs738409 MM genotype affected the levels of 
DNA methylation and transcription. The methylation of CpG99 may be induced by 
environmental factors, causing decreased expression of PNPLA3 mRNA and the 
progression of fibrosis in patients with the MM genotype. The findings that the MM 
genotype affecting levels of DNA methylation and transcription are novel and could 
contribute to establishing the association of the PNPLA3 with fibrosis, although further 
analysis and larger studies are required. 
 The methylation levels of CpG99 and CpG26 in liver differed between patients 
with mild or advanced NAFLD, but not in blood, suggesting that an alternation in 
liver-specific DNA methylation levels leads to changes in transcriptional levels and 
increases the severity of the liver disease. The difference in methylation levels was highest 
in CpG26, which is located in the upstream region of PARVB transcript variant 1; however, 
this transcript was undetectable. The transcriptional levels of PNPLA3 inversely correlated 
with the methylation levels of CpG99 near the gene. Therefore, hypomethylation of CpG26 
may affect the level of the PARVB transcript variant 1 mRNA. 
 NF-κB is a key transcription factor involved in regulating inflammation [37] and 
ChIP-sequence data reveal that the binding of NF-κB to CpG26 [38]. The binding of 





may increase the binding affinity of NF-κB for DNA and facilitate the transcription of 
PARVB transcript variant 1 mRNA, a possibility that warrants further investigation. 
 In summary, our results indicate that hypermethylation of CpG99 and 
hypomethylation of CpG26 are related to the ultimate outcomes of patients with liver 
fibrosis. Genetics and epigenetic analyses suggest that PNPLA3 and PARVB are involved in 
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Fig. 1. PCR analysis of bisulfite-treated DNA. Amplicons (first set) were derived from 
bisulfite-treated DNA of the first set of patients with NAFLD, and amplicons (second set) 
were those from the second set of patients with NAFLD or chronic hepatitis C. 
 
Fig. 2. DNA methylation status of CpG99, CpG77, CpG26, and CpG101 in the livers 
of patients with mild or advanced NAFLD of the first set. The numbers in the figure 
indicate the positions of the CpG sites. 
 
Fig. 3. DNA methylation status of CpG99, CpG77, CpG26, and CpG101 in the blood 
of patients with mild or advanced NAFLD of the first set. 
 
Fig. 4. Liver mRNA levels in the first set (A) and second set (B) of patients with 
NAFLD and the correlation between DNA methylation status and mRNA levels (C). 






Table 1. Clinical characteristics of study participants. 
 NAFLD 
Chronic hepatitis C 
 1st set 2nd set 
 Mild Advanced P-value Mild Advanced P-value Mild Advanced P-value 
n 21 11 - 15 18 - 19 11 - 
Male/Female 15 / 6 4 / 7 0.072* 9/6 12/6 0.73* 11/8 8/3 0.47* 
Age (years) 47.3 ± 18.1 59.5 ± 13.5 0.042 49.8 ± 15.1 53.3 ± 14.5 0.51 54.8 ± 12.8 64.3 ± 9.7 0.031 
BMI (kg/m2) 27.7 ± 3.9 26.9 ± 4.3 0.61 29.5 ± 3.6 28.8 ± 4.6 0.65 23.1 ± 3.1 25.1 ± 6.3 0.39 
Plasma glucose (mg/dL) 99.9 ± 12.6 116.4 ± 25.2 0.12 104.7 ± 18.3 109.8 ± 19.2 0.44 107.3 ± 29.4 111.8 ± 24.6 0.67 
Hb.A1c (%) 5.8 ± 1.2 6.1 ± 1.2 0.57 5.8 ± 0.7 6 ± 0.8 0.38 5.7 ± 1.2 5.6 ± 0.8 0.78 
Fasting insulin (µU/mL) 17.4 ± 28.3 13.9 ± 7.5 0.59 13.3 ± 6 20.6 ± 9.8 0.016 10.3 ± 5.7 11.2 ± 7.1 0.73 
Total cholesterol (mg/dL) 203.2 ± 28.4 186.3 ± 37 0.21 198.6 ± 37.6 199.6 ± 30.2 0.93 195.5 ± 29.4 177.1 ± 42.1 0.24 
Triglycerides (mg/dL) 148.6 ± 69.8 124.9 ± 33.9 0.21 154.5 ± 51.1 155.4 ± 84.7 0.97 170.4 ± 125.8 116.6 ± 53.8 0.12 
HDL-cholesterol (mg/dL) 53.6 ± 15.2 54.7 ± 14.3 0.84 51.4 ± 9.8 49.3 ± 20.3 0.70 52.6 ± 16.1 52 ± 14.5 0.91 
SBP (mmHg) 127.9 ± 17.1 145.0 ± 8.9 0.07 129.9 ± 14.6 122.9 ± 12.6 0.16 125.3 ± 16.6 137.2 ± 18.8 0.10 
DBP (mmHg) 76.6 ± 12.9 84.7 ± 13.8 0.44 78.4 ± 12.2 74.4 ± 11.5 0.35 75.2 ± 10.2 82.1 ± 12.7 0.14 
AST (IU/L) 38.2 ± 19.6 67.6 ± 31.2 0.013 44.6 ± 19.7 46.7 ± 17.3 0.75 42.2 ± 19.6 73.3 ± 48.8 0.066 
ALT (IU/L) 65.0 ± 48.5 86.1 ± 51.4 0.28 69.9 ± 44.5 57.4 ± 29.9 0.36 50.3 ± 30 68.8 ± 52.2 0.30 
Ferritin (ng/ml) 240.8 ± 178.5 271.1 ± 211.9 0.69 183.2 ± 90.7 200 ± 90.5 0.60 161.5 ± 122.1 336.4 ± 375.4 0.16 
Hyaluronic acid (ng/dL) 36.6 ± 38.2 101.3 ± 99.4 0.061 32.5 ± 24 82.6 ± 91 0.037 72 ± 51.2 235.6 ± 240.6 0.049 
Type IV collagen 7s (ng/dL) 4.2 ± 0.8 6.4 ± 2.3 0.010 4.4 ± 0.8 6.3 ± 2.2 0.0015 5 ± 1.5 7.9 ± 2.5 0.0037 
Steatosis grade (0−3) 1.5 ± 0.7 1.5 ± 0.7 0.93 1.9 ± 0.7 1.5 ± 0.7 0.16 - - - 
Lobular inflammation (0−3) 0.9 ± 0.6 2.0 ± 0.4 4.6×10-6 1.1 ± 0.6 1.3 ± 0.5 0.27 - - - 
Hepatocyte ballooning (0−2) 0.7 ± 0.6 1.5 ± 0.5 0.0012 0.3 ± 0.5 0.5 ± 0.5 0.18 - - - 
NAS (0−8) 3.1 ± 1.5 5.0 ± 1.0 2.9×10-4 3.2 ± 1.4 3.3 ± 1.1 0.86 - - - 
Fibrosis stage (0−4) 0.7 ± 0.5 2.5 ± 0.5 1.3×10-8 0.8 ± 0.4 2.6 ± 0.6 3.4×10-11 1.2 ± 0.7 3.3 ± 0.5 3.2×10-10 
  
Obesity (%) 17 (81.0) 9 (81.8) 1.00 12 (80.0) 13 (72.2) 0.70 5 (26.3) 5 (45.5) 0.43 
Type 2 diabetes (%) 4 (19.0) 4 (36.4) 0.40 3 (20.0) 6 (33.3) 0.46 3 (15.8) 5 (45.5) 0.10 
Impaired fasting glucose (%) 5 (23.8) 5 (45.5) 0.25 5 (33.3) 8 (44.4) 0.72 5 (26.3) 5 (45.5) 0.43 
Dyslipidemia (%) 12 (57.1) 8 (72.7) 0.46 7 (46.7) 10 (55.6) 0.73 2 (10.5) 0 (0.0) 0.52 
Hypertension (%) 7 (33.3) 5 (45.5) 0.70 11 (73.3) 9 (50.0) 0.28 9 (47.4) 8 (72.7) 0.26 
Genotype rs738409 (II/IM/MM) 2/9/10 2/4/5 0.77 4/7/4 2/8/8 0.48 7/5/7 2/3/6 0.56 
Values are shown as means ± SD. 
  
Table 2. Comparison of liver genomic methylation levels in the CpG99 region in patients with NFALD and those with chronic hepatitis C according to the stage of fibrosis. 
Position 
(bp) 
1st set of NAFLD 2nd set of NAFLD NAFLD Meta-analysis Chronic hepatitis C 
Stages 0-1 
(n = 21) 
Stages 2-4 
(n = 11) 
P-value 
Stages 0-1 
(n = 15) 
Stages 2-4 
(n = 18) 
P-value P-value Q-value 
Stages 0-2 
(n = 19) 
Stages 3-4 
(n = 11) 
P-value Q-value 
44,320,033 5 ± 4 7 ± 4 0.14 4 ± 2 4 ± 2 0.96 0.33 0.41 5 ± 3 8 ± 3 0.05 0.067 
44,320,040 4 ± 4 6 ± 6 0.31 4 ± 2 5 ± 3 0.26 0.12 0.20 4 ± 3 6 ± 5 0.18 0.21 
44,320,162 8 ± 5 7 ± 4 0.77 8 ± 2 8 ± 2 0.58 0.83 0.84 10 ± 3 10 ± 2 0.74 0.76 
44,320,188 7 ± 5 11 ± 5 0.034 8 ± 2 11 ± 5 0.079 0.0075 0.035 11 ± 5 16 ± 5 0.010 0.031 
44,320,198 6 ± 5 9 ± 3 0.036 6 ± 2 9 ± 5 0.028 0.0059 0.029 8 ± 4 14 ± 4 8.4×10-4 0.016 
44,320,295 5 ± 6 7 ± 4 0.43 4 ± 2 8 ± 4 0.0077 0.022 0.062 7 ± 4 11 ± 4 0.0038 0.021 
44,320,300 7 ± 6 8 ± 6 0.68 5 ± 2 9 ± 6 0.022 0.069 0.14 8 ± 4 13 ± 5 0.011 0.031 
44,320,303 5 ± 5 7 ± 5 0.35 5 ± 2 7 ± 4 0.075 0.061 0.12 8 ± 4 11 ± 4 0.028 0.046 
44,320,317 9 ± 6 11 ± 8 0.51 10 ± 4 12 ± 3 0.11 0.10 0.18 12 ± 5 19 ± 5 0.0012 0.016 
44,320,329 15 ± 9 24 ± 10 0.017 18 ± 4 21 ± 7 0.22 0.012 0.043 21 ± 8 33 ± 9 0.0013 0.016 
44,320,351 4 ± 5 12 ± 7 0.0036 7 ± 2 9 ± 5 0.079 4.4×10-4 0.010 8 ± 4 15 ± 5 0.0021 0.016 
44,320,377 5 ± 4 7 ± 5 0.26 5 ± 2 6 ± 2 0.028 0.021 0.061 6 ± 4 9 ± 2 0.011 0.031 
Data represent the mean ± SD. Mean methylation levels >5% are indicated. 
 
  
Table 3. Comparison of liver genomic methylation levels in the CpG26 region in patients with NFALD and those with chronic hepatitis C according to the stage of fibrosis. 
Position 
(bp) 
1st set of NAFLD 2nd set of NAFLD NAFLD Meta-analysis Chronic hepatitis C 
Stages 0-1 
(n = 21) 
Stages 2-4 
(n = 11) 
P-value 
Stages 0-1 
(n = 15) 
Stages 2-4 
(n = 18) 
P-value P-value Q-value 
Stages 0-2 
(n = 19) 
Stages 3-4 
(n = 11) 
P-value Q-value 
44,392,061 48 ± 10 38 ± 8 0.0048 33 ± 5 30 ± 7 0.14 0.0046 0.024 27 ± 6 23 ± 4 0.065 0.081 
44,392,067 48 ± 10 37 ± 9 0.0045 34 ± 5 30 ± 7 0.13 0.0032 0.020 28 ± 6 24 ± 4 0.029 0.046 
44,392,082 48 ± 9 37 ± 9 0.0060 36 ± 5 32 ± 7 0.11 0.0025 0.020 28 ± 6 24 ± 3 0.0094 0.030 
44,392,120 50 ± 11 39 ± 8 0.0039 45 ± 7 43 ± 9 0.41 0.018 0.060 37 ± 6 30 ± 5 0.0021 0.016 
44,392,126 49 ± 9 38 ± 8 0.0014 45 ± 7 43 ± 8 0.47 0.0093 0.041 37 ± 5 30 ± 6 0.0037 0.021 
44,392,143 49 ± 10 39 ± 7 0.0027 47 ± 6 44 ± 8 0.36 0.012 0.043 39 ± 5 31 ± 6 0.0014 0.016 
44,392,159 44 ± 9 35 ± 8 0.0085 43 ± 6 41 ± 7 0.47 0.027 0.074 36 ± 5 27 ± 6 7.3×10-4 0.016 
44,392,179 53 ± 14 41 ± 7 0.0025 51 ± 8 50 ± 9 0.63 0.040 0.098 44 ± 6 34 ± 7 0.0017 0.016 
44,392,184 54 ± 14 41 ± 7 0.0014 51 ± 7 50 ± 9 0.69 0.038 0.096 45 ± 6 34 ± 7 0.0010 0.016 
44,392,188 53 ± 13 40 ± 8 0.0014 51 ± 8 50 ± 9 0.85 0.051 0.11 44 ± 7 34 ± 8 0.0018 0.016 
44,392,191 52 ± 13 39 ± 8 0.0010 51 ± 8 49 ± 8 0.55 0.019 0.060 43 ± 6 33 ± 7 6.3×10-4 0.016 
44,392,230 59 ± 11 48 ± 8 0.0018 56 ± 7 53 ± 8 0.42 0.014 0.049 48 ± 6 40 ± 10 0.018 0.035 
44,392,265 70 ± 11 58 ± 8 0.0023 70 ± 9 65 ± 8 0.16 0.0035 0.020 63 ± 8 50 ± 11 0.0047 0.023 
44,392,310 77 ± 10 65 ± 10 0.0058 51 ± 16 41 ± 9 0.035 3.4×10-4 0.010 38 ± 8 31 ± 9 0.044 0.062 
44,392,326 74 ± 9 62 ± 8 0.0016 46 ± 8 40 ± 8 0.055 4.8×10-4 0.010 36 ± 7 30 ± 8 0.028 0.046 
44,392,333 73 ± 9 62 ± 10 0.0042 49 ± 8 43 ± 9 0.038 3.9×10-4 0.010 38 ± 7 32 ± 8 0.038 0.055 
44,392,341 71 ± 9 61 ± 7 0.0030 50 ± 9 44 ± 9 0.070 0.0013 0.015 39 ± 7 34 ± 7 0.063 0.080 
44,392,343 79 ± 10 68 ± 7 0.0020 57 ± 14 50 ± 9 0.079 0.0012 0.015 45 ± 7 39 ± 8 0.034 0.051 
44,392,351 77 ± 9 68 ± 8 0.0088 58 ± 8 52 ± 9 0.077 0.0031 0.020 47 ± 7 41 ± 8 0.070 0.087 
44,392,365 69 ± 9 58 ± 7 0.0017 54 ± 8 50 ± 10 0.25 0.0042 0.023 45 ± 8 38 ± 8 0.016 0.035 
44,392,384 64 ± 11 52 ± 8 0.0011 58 ± 8 54 ± 10 0.15 0.0027 0.020 47 ± 7 39 ± 9 0.018 0.035 
  
44,392,410 65 ± 10 50 ± 9 2.6×10-4 58 ± 10 54 ± 11 0.29 0.0021 0.019 48 ± 8 38 ± 10 0.012 0.032 
44,392,418 68 ± 10 55 ± 9 6.7×10-4 63 ± 10 58 ± 11 0.17 0.0014 0.015 53 ± 10 41 ± 11 0.0089 0.030 
44,392,454 74 ± 12 66 ± 10 0.061 67 ± 9 65 ± 10 0.43 0.079 0.15 58 ± 10 47 ± 11 0.018 0.035 
44,392,456 74 ± 11 65 ± 10 0.022 68 ± 11 63 ± 11 0.15 0.011 0.043 57 ± 11 47 ± 11 0.020 0.038 
44,392,469 76 ± 12 68 ± 9 0.028 71 ± 11 65 ± 10 0.14 0.015 0.051 59 ± 10 49 ± 12 0.021 0.039 
44,392,479 71 ± 13 64 ± 13 0.16 65 ± 13 59 ± 12 0.20 0.060 0.12 53 ± 11 43 ± 9 0.0069 0.026 
44,392,495 74 ± 14 67 ± 12 0.13 65 ± 10 59 ± 13 0.17 0.048 0.11 54 ± 9 47 ± 8 0.035 0.052 
44,392,508 72 ± 15 66 ± 15 0.26 62 ± 13 59 ± 10 0.54 0.23 0.30 51 ± 9 44 ± 7 0.015 0.035 
44,392,516 73 ± 15 66 ± 14 0.20 61 ± 13 58 ± 9 0.50 0.17 0.25 51 ± 8 43 ± 7 0.012 0.032 
44,392,529 73 ± 15 65 ± 16 0.24 58 ± 9 56 ± 9 0.52 0.20 0.27 49 ± 9 42 ± 7 0.018 0.035 
44,392,607 90 ± 6 89 ± 3 0.38 82 ± 8 81 ± 11 0.63 0.40 0.48 76 ± 10 69 ± 10 0.085 0.10 
44,392,616 92 ± 4 89 ± 5 0.14 86 ± 7 85 ± 11 0.74 0.18 0.26 80 ± 10 73 ± 9 0.053 0.071 
44,392,618 90 ± 5 89 ± 4 0.36 84 ± 7 83 ± 12 0.87 0.49 0.55 78 ± 10 70 ± 10 0.053 0.071 
44,392,627 86 ± 7 81 ± 6 0.060 80 ± 9 77 ± 12 0.49 0.10 0.18 72 ± 11 61 ± 12 0.017 0.035 
44,392,639 87 ± 6 83 ± 7 0.14 80 ± 7 79 ± 13 0.73 0.21 0.28 74 ± 11 63 ± 13 0.027 0.046 
44,392,658 76 ± 26 81 ± 18 0.48 78 ± 19 81 ± 14 0.62 0.43 0.50 73 ± 20 68 ± 18 0.46 0.48 
44,392,664 93 ± 4 90 ± 4 0.16 88 ± 5 87 ± 9 0.58 0.18 0.26 84 ± 8 77 ± 10 0.047 0.066 
44,392,668 94 ± 5 93 ± 4 0.59 89 ± 5 91 ± 7 0.38 0.78 0.81 88 ± 8 81 ± 9 0.054 0.071 
44,392,687 92 ± 5 92 ± 3 0.83 90 ± 6 88 ± 7 0.40 0.64 0.71 86 ± 7 79 ± 9 0.032 0.050 
44,392,731 68 ± 24 71 ± 14 0.62 73 ± 14 75 ± 8 0.55 0.46 0.53 69 ± 17 66 ± 15 0.61 0.63 
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Supplementary Fig. 1. Bisulfite sequence analysis. A; Results of bisulfite sequencing. B; Electrophoresis of amplicons. The numbers 




Supplementary Fig. 2. Coverage of CpG99, CpG71, CpG26, and CpG101 in the liver and blood of patients with NAFLD or chronic 









Supplementary Fig. 3. Methylation of non-CpG sites of CpG99, CpG71, CpG26, and CpG101 in the liver and blood DNAs of the 
first set of patients with NAFLD. A; CHH in liver. B; CHG in liver. C; CHH in blood. D; CHG in blood.
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Supplementary Fig. 4. DNA methylation status of CpG99 and CpG26 in the DNAs of livers and blood of patients with mild and 
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Supplementary Fig. 5. mRNA levels of PNPLA3 of the of rs738409 genotype (A) and correlation between DNA methylation status 
and mRNA levels in the liver of patients with NAFLD (B). Bars represent the mean ± SD. Data are shown with trend lines for the 
NAFLD with MM and IM+II genotypes. 
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For the 1st set      
CpG99 1 PN_F7 GATATGTAGTGTTTGTTGGAGTTTTGGA PN_R4 AAATATCTTAAATCCCTCAATCCCCAAA 1132 





PAv1_R1 CCTCCTACTACCTAACTCTAAATACATC 628 
CpG26 3-2 PAv1_F3 AGATATGATGTATTTAGAGTTAGGTAGT PAv1_R3 TCTTTACTTCAATATCCCTAATATTACA 224 
CpG101 4-1 PAv2_F3 TTGTTGAGTAGTTATTAGTTAGAGGTAA PAv2_R3 AACCCTTCAAAACTAAAAATTATCCCTA 740 
CpG101 4-2 PAv2_F8 GGGTTTGGTTTTTGGTAGAAGTTTAATA PAv2_R5 CAAACCTCCCAAACCTCAACCCTACAC 1026 
For the 2nd set      
CpG99 5 PN_addF3 GGAGTGGGTGTTTTTTAGGT PN_R4 AAATATCTTAAATCCCTCAATCCCCAAA 491 
CpG26 6-1 PAv1_addF2 GAGGGTTTAATTAGTTGGTGAAGG PAv1_addR2 CCAATCCCAAAACTTCTCCT 287 













PNPLA3 qPN_F2 CCTGTGGAATCTGCCATTGCG qPN_R2 TCCAGGTCCCAAATGCCAGTG 153 
SAMM50 qSA_F1 TTGATTGACACATGTCAAGGTG qSA_R1 AGGCAGTATGGTACTTGGCCT 147 
PARVB variant 2 qPAv2_F1 CCCCGCAGGATGAAGAAGGA qPAv2_R1 AAGAATGCCATCAACTCACCG 121 




Supplementary Table 3. Number of sites and methylation levels of 4 CpG islands. 
 CpG sites CHH sites CHG sites 
     Average methylation (%)   Average methylation (%) 
CpG island 
ID 
No. of sites No. of sites Liver Blood No. of sites Liver Blood 
Total Analyzed Total Analyzed Mild Advanced Mild Advanced Total Analyzed Mild Advanced Mild Advanced 
1st set of NAFLD               
CpG99 117 117 202 201 0.5 1.0 0.5 0.5 89 89 0.6 1.1 0.8 0.7 
CpG71 66 66 146 146 0.3 0.4 0.5 0.5 64 64 0.3 0.4 0.4 0.5 
CpG26 42 42 105 105 0.7 0.6 1.0 1.1 55 55 0.5 0.5 0.8 0.8 
CpG101 144 124 294 263 6.0 5.8 6.4 6.7 133 116 5.7 5.5 6.3 6.6 
2nd set of NAFLD               
CpG99 42 42 71 71 0.5 0.4 - - 30 30 1.1 1.0 - - 
CpG26 41 41 91 91 0.7 0.6 - - 50 50 0.5 0.5 - - 
Chronic Hepatitis C               
CpG99 42 42 71 71 0.3 0.4 - - 30 30 1.0 1.0 - - 
CpG26 41 41 91 91 0.5 0.4 - - 50 50 0.3 0.3 - - 
CpG, CHH, and CHG sites which coverage <50× in more than 2 samples were excluded from the analysis. 
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Supplementary Table 4. Comparison of liver genomic methylation levels in the CpG99 




MM genotype IM or II genotypes 
Stages 0-1 
(n = 14) 
Stages 2-4 
(n = 13) 
P-value 
Stages 0-1 
(n = 22) 
Stages 2-4 
(n = 16) 
P-value 
44,320,033 4 ± 3 6 ± 4 0.22 5 ± 4 5 ± 3 0.92 
44,320,040 3 ± 2 6 ± 6 0.090 5 ± 4 5 ± 3 0.95 
44,320,162 9 ± 5 9 ± 4 0.89 7 ± 4 7 ± 3 0.92 
44,320,188 8 ± 5 12 ± 5 0.018 7 ± 4 10 ± 4 0.099 
44,320,198 6 ± 5 11 ± 4 0.017 6 ± 4 8 ± 4 0.11 
44,320,295 7 ± 7 7 ± 4 0.87 4 ± 2 7 ± 4 0.0050 
44,320,300 7 ± 5 10 ± 6 0.26 6 ± 5 8 ± 5 0.31 
44,320,303 5 ± 5 7 ± 5 0.40 5 ± 3 7 ± 4 0.094 
44,320,317 9 ± 5 12 ± 5 0.12 10 ± 5 11 ± 5 0.47 
44,320,329 16 ± 5 24 ± 9 0.0075 17 ± 8 21 ± 8 0.21 
44,320,351 4 ± 3 13 ± 7 4.3×10-4 6 ± 4 8 ± 4 0.19 
44,320,377 5 ± 3 8 ± 3 0.018 5 ± 4 5 ± 3 0.57 
Data represent the mean ± SD. Mean methylation levels >5% are indicated. 
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Supplementary Table 5. Comparison of liver genomic methylation levels in the CpG26 




MM genotype IM or II genotypes 
Stages 0-1 
(n = 14) 
Stages 2-4 
(n = 13) 
P-value 
Stages 0-1 
(n = 22) 
Stages 2-4 
(n = 16) 
P-value 
44,392,061 45 ± 13 33 ± 9 0.015 40 ± 10 33 ± 8 0.014 
44,392,067 45 ± 13 33 ± 9 0.011 41 ± 9 33 ± 8 0.013 
44,392,082 45 ± 11 35 ± 9 0.017 41 ± 9 33 ± 7 0.0051 
44,392,120 48 ± 9 41 ± 10 0.082 47 ± 10 41 ± 7 0.036 
44,392,126 48 ± 9 41 ± 10 0.089 47 ± 8 41 ± 7 0.019 
44,392,143 49 ± 8 43 ± 10 0.088 48 ± 9 42 ± 7 0.035 
44,392,159 44 ± 8 40 ± 10 0.28 44 ± 8 38 ± 6 0.020 
44,392,179 52 ± 8 46 ± 11 0.11 52 ± 13 47 ± 8 0.13 
44,392,184 53 ± 8 46 ± 11 0.083 52 ± 13 47 ± 7 0.11 
44,392,188 52 ± 7 46 ± 12 0.11 53 ± 13 47 ± 8 0.14 
44,392,191 52 ± 8 44 ± 11 0.045 51 ± 13 46 ± 8 0.11 
44,392,230 58 ± 7 50 ± 10 0.034 58 ± 11 52 ± 7 0.065 
44,392,265 68 ± 5 62 ± 11 0.078 71 ± 13 63 ± 7 0.020 
44,392,310 67 ± 17 50 ± 15 0.012 66 ± 18 50 ± 15 0.0085 
44,392,326 65 ± 17 47 ± 14 0.0057 60 ± 16 50 ± 13 0.036 
44,392,333 66 ± 14 48 ± 14 0.0027 62 ± 15 51 ± 13 0.033 
44,392,341 63 ± 13 49 ± 12 0.0076 62 ± 14 52 ± 12 0.025 
44,392,343 72 ± 15 56 ± 14 0.0067 69 ± 17 57 ± 12 0.020 
44,392,351 71 ± 13 57 ± 13 0.010 68 ± 13 59 ± 11 0.038 
44,392,365 64 ± 11 52 ± 10 0.012 62 ± 11 54 ± 9 0.024 
44,392,384 62 ± 8 53 ± 11 0.020 62 ± 11 54 ± 8 0.013 
44,392,410 61 ± 8 51 ± 11 0.023 63 ± 12 54 ± 10 0.014 
44,392,418 65 ± 8 57 ± 12 0.045 67 ± 12 57 ± 9 0.0044 
44,392,454 69 ± 11 66 ± 12 0.53 73 ± 11 64 ± 8 0.013 
44,392,456 70 ± 10 64 ± 11 0.19 73 ± 12 63 ± 10 0.0075 
44,392,469 71 ± 10 68 ± 11 0.42 76 ± 13 65 ± 8 0.0023 
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44,392,479 65 ± 14 63 ± 13 0.76 70 ± 13 59 ± 11 0.0053 
44,392,495 67 ± 14 66 ± 11 0.79 72 ± 12 58 ± 13 0.0032 
44,392,508 64 ± 16 66 ± 12 0.68 70 ± 14 58 ± 11 0.0055 
44,392,516 65 ± 16 65 ± 12 0.99 70 ± 15 58 ± 11 0.0064 
44,392,529 64 ± 16 64 ± 13 0.99 68 ± 14 56 ± 12 0.0063 
44,392,607 85 ± 6 83 ± 12 0.48 88 ± 9 85 ± 7 0.20 
44,392,616 88 ± 5 84 ± 12 0.31 91 ± 7 89 ± 6 0.31 
44,392,618 86 ± 5 84 ± 13 0.55 89 ± 8 87 ± 5 0.38 
44,392,627 82 ± 7 78 ± 14 0.38 84 ± 10 79 ± 7 0.069 
44,392,639 83 ± 5 78 ± 14 0.19 84 ± 8 82 ± 7 0.50 
44,392,658 76 ± 22 81 ± 15 0.52 77 ± 25 81 ± 16 0.50 
44,392,664 91 ± 3 86 ± 10 0.090 91 ± 6 91 ± 4 0.83 
44,392,668 91 ± 5 90 ± 7 0.46 92 ± 5 93 ± 4 0.42 
44,392,687 89 ± 4 88 ± 8 0.53 92 ± 6 92 ± 3 0.52 
44,392,731 72 ± 20 74 ± 11 0.73 69 ± 21 74 ± 11 0.36 
Data represent the mean ± SD. 
